Iduronate-2-sulfatase gene therapy

Drug Profile

Iduronate-2-sulfatase gene therapy

Alternative Names: Hunter syndrome gene therapy

Latest Information Update: 23 Sep 2013

Price : $50

At a glance

  • Originator University of Minnesota
  • Class Iduronate sulfatases
  • Mechanism of Action Iduronate sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mucopolysaccharidosis II

Most Recent Events

  • 31 Dec 2007 Discontinued - Phase-II for Mucopolysaccharidosis II in USA (Infusion)
  • 31 Dec 2007 Discontinued - Preclinical for Mucopolysaccharidosis II in Italy (unspecified route)
  • 11 Dec 2003 No development reported - Phase-II for Mucopolysaccharidosis type II in USA (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top